Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 5, 2000, Pages 655-662

  Zhanel, George G ^a,b,c   Karlowsky, James A ^a,b,c   Low, Donald E ^d   Hoban, Daryl J ^a,c  

^a Faculty of Medicine   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFOTAXIME; CEFPROZIL; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; LORACARBEF; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CANADA; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY SYSTEM;

EID: 0034057602     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.5.655     Document Type: Article

References (16)

1. Jorgensen, J. H., Doern, G. V., Maher, L. A., Howell, A. W. & Redding, J. S. (1990). Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 34, 2075-80.
2. Doern, G. V., Pfaller, M. A., Kugler, K., Freeman, J. & Jones, R. N. (1998). Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clinical Infectious Diseases 27, 764-70.
3. Doern, G. V., Jones, R. N., Pfaller, M. A. & Kugler, K. (1999). Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy 43, 385-9.
4. Scriver, S. R., Walmsley, S. L., Kau, C. L, Hoban, D. J., Brunton, J., McGeer, A. et al. (1994). Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Canadian Haemophilus Study Group. Antimicrobial Agents and Chemotherapy 38, 1678-80.
5. Scriver, S. R., Low, D. E., Simor, A. E., Toye, B., McGeer, A. & Jaeger, R. (1992). Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group. Journal of Clinical Microbiology 30, 2284-9.
6. Tremblay, L. D., L'Ecuyer, J., Provencher, P. & Bergeron, M. G. (1990). Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Canadian Haemophilus Study Group. Canadian Medical Association Journal 143, 895-901.
7. Doern, G. V., Brueggemann, A. B., Pierce, G., Hogan, T., Holley, H. P., Jr & Rauch, A. (1996). Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 2884-6.
8. Jones, R. N., Jacobs, M. R., Washington, J. A. & Pfaller, M. A. (1997). A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diagnostic Microbiology and Infectious Diseases 27, 75-83.
9. Doern, G. V., Brueggemann, A. B., Pierce, G., Holley, H. P., Jr & Rauch, A. (1997). Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrobial Agents and Chemotherapy 41, 292-7.
10. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA.
11. National Committee for Clinical Laboratory Standards. (1999). Performance Standards for Antimicrobial Susceptibility Testing - Ninth Informational Supplement M100-S9. NCCLS, Villanova, PA.
12. Dagan, R., Abramson, O., Leibovitz, E., Greenberg, D., Lang, R., Goshen, S. et al. (1997). Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? Journal of Infectious Diseases 176, 1253-9.
13. Doern, G. V. (1992). In vitro activity of loracarbef and effects of susceptibility test methods. American Journal of Medicine 92, Suppl. 6A, 75-155.
14. Doern, G. V. (1994). Does there exist a rational, objective in vitro basis for the management of selected infections of the respiratory tract? Infectious Diseases and Clinical Practice 3, 75-80.
15. Farmer, T. & Reading, C. (1982). β-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid. Antimicrobial Agents and Chemotherapy 21, 506-8.
16. Stobberingh, E. E., van Eck, H. J., Houben, A. W. & van Boven, C. P. A. (1986). Analysis of the relationship between ampicillin resistance and β-lactamase production in Branhamella catarrhalis. Drugs 31, Suppl. 3, 23-7.